Statins can reduce sepsis deaths, study suggests
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests.
Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients.
The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins.
Some 14.3% of 6,000 sepsis patients who were given statins died within 28 days.
This is compared with 23.4% of 6,000 patients who did not receive statin therapy.
The research team from China said that this equates to a 39% reduced risk of death within a month.
The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4% of statin patients died while in the intensive care unit compared with 13.6% of those who did not receive statins.
And during their overall hospital stay, some 11.5% of sepsis patients who were given statins died, compared with 19.1% of sepsis patients who did not take statins.
However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days.
'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs.
In the UK, 245,000 people are affected by sepsis every year.
UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings.
Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood.
But experts said that they also have other benefits, including reducing inflammation and antibacterial effects.
The research team called for larger trials to confirm their findings.
'Our large, matched cohort study found that treatment with statins was associated with a 39% lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China.
'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.'
Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis.
'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial.
'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
33 minutes ago
- The Independent
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
Daily Mail
4 hours ago
- Daily Mail
Hidden 'fingerprints' found in the Bible after thousands of years rewrite the story of the Ark of the Covenant
Scientists have uncovered hidden patterns in the Bible that challenge ancient beliefs about its origins. Using artificial intelligence, they discovered 'fingerprints' in text throughout the Old Testament, suggesting multiple people wrote the stories. The traditional Jewish and Christian understanding is that Moses wrote the first five books of the Old Testament, including stories about creation, Noah's flood and the Ark of the Covenant. The new study found three distinct writing styles with distinct vocabulary, tone and focus areas, suggesting multiple authors and sources contributed to the books over time. Researchers used AI analyzed for 50 chapters across five books, uncovering inconsistencies in language and content, repeated stories, shifts in tone and internal contradictions. The theory that scripture had multiple authors was first proposed more than 200 years ago, but was dismissed due to religions debate, lack of technology and nuances of biblical text. Thomas Römer, a biblical expert from the Collège de France and co-author of the study, told The Times of Israel: 'There are no authors of the Bible in the modern sense. 'The original versions of the scrolls were continuously reworked and rewritten by redactors who added, altered, and sometimes also omitted parts of the former texts.' The traditional Jewish and Christian understanding is that Moses wrote the first five books of the Old Testament. However, the new study has found evidence suggesting that multiple people may have contributed to these texts. While the Bible portrays Moses as a key historical figure, most scholars today view him as a legendary figure, or at least a composite character, rather than a literal historical person. The Old Testament was written over a period of approximately 1000 years, starting roughly around 1400 BC and ending around 400 BC. It is comprised of 39 books, focusing around God's covenant with humanity, His relationship with the Israelites, and the promise of a Messiah who would bring salvation and redemption. In several books, Moses is attributed to writing some passages. Exodus 24:4 reads: 'Moses wrote down all the words of the Lord' A similar passage is found in Deuteronomy 31:9 that states: 'Moses wrote this law and gave it to the priests...' For thousands of years, Jewish and Christian traditions held Moses to be the author because he is the central figure in the books and was seen as a prophet, lawgiver and leader capable of writing such texts. But the new study could change this long-held history. The AI examined patterns in word usage, word frequency, phrases and sentences structures as these are subtle linguistic 'fingerprints' that can reflect different authors or schools of scribes. Beyond confirming the styles, the team extended their AI method to study nine other biblical sections with disputed authorship. These included well-known stories such as the creation narrative, Noah's flood and the Ark of the Covenant accounts. According to the Bible, the Ark of the Covenant was built by the Israelites shortly after they fled Egypt around the 13th century BC. Moses then placed the Ten Commandments inside. The AI algorithm compared these chapters' word usage to the three known styles, revealing new affiliations and helping clarify long-standing scholarly debates. Researchers said this new technique could revolutionize the study of ancient texts, helping to solve other authorship mysteries beyond the Bible, such as texts like the Dead Sea Scrolls or historical documents where authorship is uncertain. The three writing styles were first found when Biblical scholars noticed certain sections of the Old Testament had different vocabulary, themes and ways of writing. The first style, known as the Deuteronomic (D) corpus, focuses on laws, obedience, and clear commands. The second, the Deuteronomistic History (DtrH), narrates Israel's history, emphasizing moral lessons based on faithfulness, and the Priestly (P) style highlights rituals, priesthood and sacred spaces with formal and detailed language. Thomas Römer, a biblical expert from the Collège de France and co-author of the study, told The Times of Israel: 'Deuteronomy refers to the last book of the Torah/Pentateuch. 'There is a wide consensus that the first version of this scroll was written down in the 7th century BCE. The core of this first version was the laws that stipulate that the God of Israel had chosen only one place [Jerusalem] for the sacrificial cult.' He explained that Deuteronomistic History was also re-worked several times. And the Priestly Writings include several texts in Genesis, Exodus and Leviticus. 'These texts were written for the first time around 520 BCE in the context of the reconstruction of the Second Temple,' Römer said. 'The priestly authors and redactors want to show the importance of rituals and the different types of sacrifices.'
Daily Mail
5 hours ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'
